A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Encenicline (Primary) ; Moxifloxacin
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors FORUM Pharmaceuticals
- 16 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
- 16 Jul 2013 Status changed from active, no longer recruiting to completed.
- 14 Nov 2012 Planned end date changed from 1 May 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.